Amgen Reports Aimovig ™ (Erenumab) Met All Primary And Secondary Endpoints In Unique Phase 3b Study In Episodic Migraine Patients Who Have Failed Multiple Prior Preventive Treatments
LIBERTY is the First Migraine Prevention Trial of its Kind Conducted Specifically in Patients Who Have Tried Multiple Therapies Without Success, and are in Need of Additional Treatment Options
The Trial Met its Primary Endpoint of Percentage of Patients on Aimovig Achieving at Least a 50 Percent Reduction of Migraine Days Versus Placebo, and all Secondary Endpoints
Results Add to the Consistent Efficacy, Safety and Tolerability Profile of Aimovig Across the Spectrum of Migraine, Even in More Difficult to Treat Patients
THOUSAND OAKS, Calif., Jan. 22, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positi...
Source: Amgen News Release - January 22, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
European Commission Approves Amgen And Allergan's MVASI ® (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer
Marketing Authorization Based on Global Development Program Showing MVASI is Highly Similar to Avastin® (Bevacizumab)
First Biosimilar Bevacizumab Approved in the European Union
THOUSAND OAKS, Calif., Jan. 18, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Allergan plc. (NYSE: AGN) today announced that the European Commission (EC) has granted marketing authorization for MVASI® (biosimilar bevacizumab). MVASI is the first biosimilar bevacizumab approved by the EC and is approved for the treatment of certain types of cancers, including in combination with fluoropyrimidine-based chemotherapy for metastatic carcinoma ...
Source: Amgen News Release - January 18, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
FDA Approves Addition Of Overall Survival Data To KYPROLIS ® (carfilzomib) Label
Phase 3 Data Showed KYPROLIS and Dexamethasone Reduced the Risk of Death by 21 Percent Versus Velcade® (Bortezomib) and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Overall Survival Results Support Use of KYPROLIS in Combination With Dexamethasone as New Standard of Care
THOUSAND OAKS, Calif., Jan. 17, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) to add overall survival (OS) data from the Phase 3 head-to-head ENDEAVOR trial to the Prescribing Information for KYPROLIS® (ca...
Source: Amgen News Release - January 17, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Overall Survival Analysis From KYPROLIS ® (Carfilzomib) Phase 3 ASPIRE Trial Published in the Journal of Clinical Oncology
KYPROLIS, Lenalidomide and Dexamethasone Reduced the Risk of Death by 21 Percent Versus Lenalidomide and Dexamethasone Alone in Patients With Relapsed or Refractory Multiple Myeloma
Results Support Early Use of KYPROLIS at First Relapse
THOUSAND OAKS, Calif., Jan. 17, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Journal of Clinical Oncology published positive overall survival (OS) findings from the final analysis of the Phase 3 ASPIRE trial, which demonstrated that the addition of KYPROLIS® (carfilzomib) to lenalidomide and dexamethasone (KRd) reduced the risk of death by 21 percent versus len...
Source: Amgen News Release - January 17, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
European Medicines Agency Accepts Filing For EVENITY ™ (Romosozumab)
Application Supported by Phase 3 Data in More Than 11,000 Postmenopausal Women and Men with Osteoporosis at Increased Risk of Fracture
THOUSAND OAKS, Calif. and BRUSSELS, Jan. 7, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for EVENITY™* (romosozumab) for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. If approved in Europe, EVENITY will be a novel osteoporosis treatment that increases bone formation and reduces bone resorpti...
Source: Amgen News Release - January 8, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
FDA Approves XGEVA ® (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma
Expansion of Indication Offers Patients a New Treatment Option
Approval Based on Safety and Efficacy Data From the Largest International Multiple Myeloma Clinical Trial Ever Conducted
THOUSAND OAKS, Calif., Jan. 5, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for XGEVA® (denosumab) to expand the currently approved indication for the prevention of skeletal-related events in patients with bone metastases from solid tumors to include patients with multiple myeloma. The approval is based on da...
Source: Amgen News Release - January 5, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen To Present At The 36th Annual J.P. Morgan Healthcare Conference
THOUSAND OAKS, Calif., Jan. 4, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the 36th Annual J.P. Morgan Healthcare Conference at 8:30 a.m. PT on Tuesday, Jan. 9, 2018, in San Francisco. Robert A. Bradway, chairman and chief executive officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90 days following the event.
About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from s...
Source: Amgen News Release - January 4, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Teams Up With Cambridge Biotech Community To Select Two Startups To Receive Golden Tickets At LabCentral
Amgen Golden Tickets Provide Innovative Startup Companies With Free Lab Space to Aid in Further Advancement of Their Science
CAMBRIDGE, Mass., Dec. 14, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and LabCentral today announced that Kernal Biologics Inc. and QurAlis have won the Amgen Golden Ticket at LabCentral. The two Golden Ticket winners were chosen by an Amgen internal committee and live audience members at a "Quick Pitch" event hosted by Amgen at its Cambridge R&D and Operations facility on Dec. 11, 2017. Five finalists pitched their business plan to attendees where the audiences' input represented one vote of ...
Source: Amgen News Release - December 14, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
